Status:
COMPLETED
MEP and Neuromuscular Blocker
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Brain Tumor
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
It is important to predict the influence of the neuromuscular blocking agents on the motor evoked potential. Investigator will investigate the dose-response relationship between the degree of the neur...
Eligibility Criteria
Inclusion
- 1\. Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for elective brain tumor surgery under the monitoring of the motor evoked potential
Exclusion
- Central or peripheral neuromuscular disease
- Sensory or motor nerve disorder
- Allergy to propofol, remifentanil, and rocuronium
- Patients with pacemaker
Key Trial Info
Start Date :
March 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 13 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04768400
Start Date
March 9 2021
End Date
May 13 2022
Last Update
June 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GangnamSeverance Hospital
Seoul, South Korea